Alexion Announces Fourth Quarter 2018 Financial Results

Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing therapies. As the global leader in complement biology and inhibition for more than 20 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), as well as the first and only approved complement inhibitor to treat atypical hemolytic uremic syndrome (aHUS) and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG), and is also developing it for patients with neuromyelitis optica spectrum disorder (NMOSD)

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced fourth quarter financials.  Revenue for the quarter was USD 1,128 million or a 24 percent increase from a year ago. 

“2018 was a transformational year for Alexion. I am proud of our many accomplishments, including entering rare neurology and making SOLIRIS for gMG Alexion’s best launch ever, completing the Phase 3 program and launching ULTOMIRIS for PNH in the U.S., delivering groundbreaking Phase 3 data and submitting regulatory filings for SOLIRIS in NMOSD and rebuilding our pipeline through disciplined business development, all while continuing to grow our base business,” said Ludwig Hantson, Ph.D., Chief Executive Officer of Alexion. “As we look at 2019 and beyond, I am confident that this strong foundation positions us well to achieve our Four Pillars of growth, building durable, blockbuster franchises in PNH/aHUS, metabolics, neurology and FcRn.”

For the full year 2018, net product sales were USD 4,130.1 million compared to USD 3,549.5 million a year prior. 

1 Comment
  1. Jon Vince 7 months ago

    Honestly, when you have companies like $BMRN that are worth 18B and have been having the hardest time to generate a small profit versus $ALXN, sure seems absurd execution isn’t rewarded

Leave a Comment